Movers of most recent trading session: Office Depot, Inc. (NASDAQ:ODP), Amicus Therapeutics, Inc. (NASDAQ:FOLD)

32

Office Depot, Inc. (NASDAQ:ODP)

The company announced its last quarter financial performance results on 11/02/2016. Office Depot, Inc. (NASDAQ:ODP) belongs to Retail-Wholesale sector that declined -1.25% in value when last trading session closed at $4.74. The company has a market capitalization of $2.54 Billion. The company’s stock has a Return on Assets (ROA) of 5.1 percent, a Return on Equity (ROE) of 18.1 percent and Return on Investment (ROI) of 2.4 percent. The company reached its 52-Week high of $7.91 on Apr 7, 2016 and 52-Week low of $3.01 on Nov 1, 2016.

Earnings per share (ttm) for Office Depot, Inc. (NASDAQ:ODP) according to Finviz Data is $1.09.

The growth estimate for Office Depot, Inc. (NASDAQ:ODP) for the current quarter is 57.1 percent. The projected growth estimate for the next quarter is 20 percent. The company’s stock has grown by 22.56 percent in the past 5 years. For the next 5 years, the company is expected to grow by 11.8 percent.

This company was Initiated by Loop Capital on 13-Dec-16  to Hold.

The 7 analysts offering 12-month price forecasts for Office Depot Inc have a median target of 4.50, with a high estimate of 6.50 and a low estimate of 3.10. The median estimate represents a -5.06% decrease from the last price of 4.74.

Financial History:

Following Earnings result, share price were DOWN 16 times out of last 28 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  3  times and missed earnings  5  times.

The consensus recommendation for Office Depot, Inc. (NASDAQ:ODP) is 3. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 3. In comparison, the consensus recommendation 60 days ago was at 3, and 90 days ago was at 3 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Office Depot, Inc. to have earnings per share of $0.11.

Revenue is expected to range from 2.58 Billion to 2.9 Billion with an average of 2.71 Billion.

Company Profile:

Office Depot, Inc., together with its subsidiaries, is the one of the largest suppliers of office products and services in the world. The company sells to consumers and businesses of all sizes through its three business segments: Stores, Business Services and International.  As the largest seller of office products around the world, the Company operates under the Office Depot, Viking Office Products, Viking Direct and 4Sure.com brand names.

Amicus Therapeutics, Inc. (NASDAQ:FOLD):

Amicus Therapeutics, Inc. (NASDAQ:FOLD) belongs to Medical sector closed its last session with a gain of 0.83 percent and closed its previous trading session at $4.84. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-1.42. The company has the Market capitalization of $684.38 Million. The company’s stock has a Return on Assets (ROA) of -20.5 percent, a Return on Equity (ROE) of -55.4 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $9.99 on Dec 31, 2015 and 52-Week low of $4.7 on Dec 16, 2016.

This company was Initiated by BofA/Merrill on 18-May-16 to Buy.

The 7 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 11.00, with a high estimate of 16.00 and a low estimate of 7.00. The median estimate represents a +127.27% increase from the last price of 4.84.

Financial History:

Following Earnings result, share price were DOWN 14 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 16% percent of times. It has met expectations  1 times and missed earnings  9  times.

The consensus recommendation for Amicus Therapeutics, Inc. (NASDAQ:FOLD) is 1.4. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.29. In comparison, the consensus recommendation 60 days ago was at 1.29, and 90 days ago was at 1.33 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Amicus Therapeutics, Inc. to have earnings per share of $-0.35.

Revenue is expected to range from 2.36 Million to 4.51 Million with an average of 3.6 Million.

Company Profile:

AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.

-